MannKind stock
MNKDNASDAQMannKind Corporation, HealthcareISIN US56400P7069
39Score 39 out of 100, Weak
Price and trend
63 / 100
Price history
−21% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 14% above it.
Since March 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 83).
The price is 33% below its 52-week high. Largest decline in 20 years: 99% (February 2007 to May 2017).
Chart figures for advanced users
- SMA 50$3.57
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$3.66
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)83
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$2.28
- The lowest closing price of the last twelve months.
- Resistance$6.21
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- MannKind Corporation belongs to the Biotechnology industry (United States) and, with a market value of $1.34B, is number 164 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $348.97M (up 22.2% year on year) and earnings of $5.86M (down 78.7%).
- For fiscal 2026, analysts expect on average revenue of $440.12M (up 26.1%) and adjusted earnings per share of −$0.19.
Show more
- MEQIRI Score 39 out of 100 (Weak): rank 551 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 39.9% a year since 2020, Biotechnology median 19.4%.Growth 70
Weaknesses
- DilutionShare count up 37% since 2020.Capital allocation 18
- Interest barely coveredOperating profit covers interest only 1.1 times.Stability 34
- Loss-makingLoss of $74.82M over the last 12 months.Fundamentals 17
Its standout strength is growth, while fundamentals and valuation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
Valuation
Valuation signal
OvervaluedNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 31.7% on the twelve months before. Revenue has grown solidly since 2016, at about 8% per year. From 2016 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 82%, operating 11%, net 2%. Last 12 months: net −18%. From 2016 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 104 days
- Last reported
- 5 Nov 2026EPS reported −$0.01 (expected −$0.07)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 11.1% since 16 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$0.19−4.1%
- Revenue
- $440.12M−0.6%
- Earnings per share
- $0.00−11.1%
- Revenue
- $504.97M+0.4%
MEQIRI has stored the estimates since 16 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +24.1%2026 FUROSCIX revenue target of $110 million to $120 million reiterated.
“Chris will walk through the quarter in more detail, but we are confident the underlying business is moving in the right direction, and we remain on track to meet our full year 2026 FUROSCIX revenue target of $110 million to $120 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 May 2026 (fiscal Q1 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $725,611 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at MannKind
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 39
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Damora TherapeuticsDMRA $1.36B38
- Tyra BiosciencesTYRA $1.36B36
- Avalyn PharmaAVLN $1.36B41
- InnovivaINVA $1.35B67
- Pharma MarPHM.MC $1.31B59
- OmerosOMER $1.3B52
- UroGen PharmaURGN $1.29B36
- Inhibrx BiosciencesINBX $1.29B33
ETFs that hold MannKind
Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.08% | 0.35% | €1.25B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.04% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.04% | 0.30% | €2.22B |
Show 5 more
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.5B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.27B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.10% | €395.74M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.01% | 0.30% | €964.08M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €178.55M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 27 Feb 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.